Search NASA⌕ Search

Engineering topics

Matthews, David

Publications and source records attributed to Matthews, David.

Radio and X-Ray Observations of the Luminous Fast Blue Optical Transient AT 2020xnd

We present deep X-ray and radio observations of the fast blue optical transient (FBOT) AT 2020xnd/ZTF 20acigmel at z = 0.2433 from 13 days to 269 days after explosion. AT 2020xnd belongs to the category of optically luminous FBOTs with similarities to the archetypal event AT 2018cow. AT 2020xnd shows luminous radio emission reaching L ν ≈ 8 × 10 29 erg s -1 Hz -1 at 20 GHz and 75 days post-explosion, accompanied by luminous and rapidly fading soft X-ray emission peaking at L X ≈ 6 × 10 42 erg s -1 . Interpreting the radio emission in the context of synchrotron radiation from the explosion's shock interaction with the environment, we find that AT 2020xnd launched a high-velocity outflow (v ~ 0.1c–0.2c) propagating into a dense circumstellar medium (effective $\dot{M}\approx {10}^{-3}\,{M}_{\odot }$ yr -1 for an assumed wind velocity of v w = 1000 km s -1 ). Similar to AT 2018cow, the detected X-ray emission is in excess compared to the extrapolated synchrotron spectrum and constitutes a different emission component, possibly powered by accretion onto a newly formed black hole or neutron star. These properties make AT 2020xnd a high-redshift analog to AT 2018cow, and establish AT 2020xnd as the fourth member of the class of optically luminous FBOTs with luminous multiwavelength counterparts.

79 ASTRONOMY AND ASTROPHYSICS↗

Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target

With increasing drug resistance in tuberculosis (TB) patient populations, there is an urgent need for new drugs. Ideally, new agents should work through novel targets so that they are unencumbered by preexisting clinical resistance to current treatments. Benzofuran 1 was identified as a potential lead for TB inhibiting a novel target, the thioesterase domain of Pks13. Although, having promising activity against Mycobacterium tuberculosis, its main liability was inhibition of the hERG cardiac ion channel. This article describes the optimization of the series toward a preclinical candidate. Despite improvements in the hERG liability in vitro, when new compounds were assessed in ex vivo cardiotoxicity models, they still induced cardiac irregularities. Further series development was stopped because of concerns around an insufficient safety window. However, the demonstration of in vivo activity for multiple series members further validates Pks13 as an attractive novel target for antitubercular drugs and supports development of alternative chemotypes.

60 APPLIED LIFE SCIENCES↗

Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis

Malaria and cryptosporidiosis, caused by apicomplexan parasites, remain major drivers of global child mortality. New drugs for the treatment of malaria and cryptosporidiosis, in particular, are of high priority; however, there are few chemically validated targets. The natural product cladosporin is active against blood- and liver-stage Plasmodium falciparum and Cryptosporidium parvum in cell-culture studies. Target deconvolution in P. falciparum has shown that cladosporin inhibits lysyl-tRNA synthetase (PfKRS1). Here, we report the identification of a series of selective inhibitors of apicomplexan KRSs. Following a biochemical screen, a small-molecule hit was identified and then optimized by using a structure-based approach, supported by structures of both PfKRS1 and C. parvum KRS (CpKRS). In vivo proof of concept was established in an SCID mouse model of malaria, after oral administration (ED 90 = 1.5 mg/kg, once a day for 4 d). Furthermore, we successfully identified an opportunity for pathogen hopping based on the structural homology between PfKRS1 and CpKRS. This series of compounds inhibit CpKRS and C. parvum and Cryptosporidium hominis in culture, and our lead compound shows oral efficacy in two cryptosporidiosis mouse models. X-ray crystallography and molecular dynamics simulations have provided a model to rationalize the selectivity of our compounds for PfKRS1 and CpKRS vs. (human) HsKRS. Our work validates apicomplexan KRSs as promising targets for the development of drugs for malaria and cryptosporidiosis.

59 BASIC BIOLOGICAL SCIENCES↗

Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential

Drug therapy is the mainstay of antimalarial therapy, yet current drugs are threatened by the development of resistance. In an effort to identify new potential antimalarials, we have undertaken a lead optimization program around our previously identified triazolopyrimidine-based series of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors. The X-ray structure of PfDHODH was used to inform the medicinal chemistry program allowing the identification of a potent and selective inhibitor (DSM265) that acts through DHODH inhibition to kill both sensitive and drug resistant strains of the parasite. This compound has similar potency to chloroquine in the humanized SCID mouse P. falciparum model, can be synthesized by a simple route, and rodent pharmacokinetic studies demonstrated it has excellent oral bioavailability, a long half-life and low clearance. These studies have identified the first candidate in the triazolopyrimidine series to meet previously established progression criteria for efficacy and ADME properties, justifying further development of this compound toward clinical candidate status.

59 BASIC BIOLOGICAL SCIENCES↗

Linear Extrusion 400 Tons/Day Dry Solids Pump

Pratt & Whitney Rocketdyne (PWR) has developed an innovative gasifier concept that uses rocket engine experience to significantly improve gasifier performance, life, and cost compared to current state-of-the-art systems. The PWR gasifier concept uses a compact and highly efficient (>50%) dry solids pump that has excellent availability (>99.5%). PWR is currently developing this dry solids pump under a U.S. Department of Energy (DOE) cooperative agreement. The conceptual design on two dry solids pumps were completed under this agreement and one pump concept was selected for preliminary design. A preliminary design review (PDR) of the selected pump was presented on September 20, 2007 to PWR management and numerous technical specialists. Feedback from the PDR review team has been factored into the design and a Delta-PDR was held on April 9, 2008.

42 ENGINEERING↗